# Prevention of bicalutamide-induced breast events in patients with prostate cancer: a meta-analysis of randomized controlled trials

## TL;DR

This study finds that tamoxifen is most effective in preventing breast issues caused by bicalutamide in prostate cancer patients, with radiotherapy as a good alternative.

## Contribution

A meta-analysis comparing the effectiveness of tamoxifen, anastrozole, and radiotherapy in preventing bicalutamide-induced breast events.

## Key findings

- Tamoxifen reduced breast events by 82% compared to bicalutamide alone.
- Radiotherapy reduced gynecomastia risk by 52% and breast pain by 34%.
- Anastrozole showed no significant benefit in preventing breast events.

## Abstract

This study aimed to quantitatively assess the effectiveness of tamoxifen, anastrozole, and radiotherapy in preventing bicalutamide-induced breast events—specifically gynecomastia and breast pain—in patients with prostate cancer.

A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted according to PRISMA-P guidelines. A comprehensive search was performed in PubMed, Scopus, and Web of Science for English-language studies without temporal restrictions. Studies were included if they involved prostate cancer patients treated with bicalutamide receiving preventive interventions (tamoxifen, anastrozole, or radiotherapy) compared to bicalutamide alone (or bicalutamide plus placebo/sham). Data extraction focused on the incidence of gynecomastia and breast pain, and study quality was assessed using the Jadad scale. Risk ratios (RR) with 95% confidence intervals (CI) were calculated using fixed- or random-effects models, and heterogeneity was evaluated with the I² statistic. Publication bias was explored via funnel plots and the trim-and-fill method.

Nine RCTs met the inclusion criteria. Tamoxifen significantly reduced the risk of breast events by 82% (RR: 0.18, 95% CI: 0.08–0.38 for gynecomastia and RR: 0.18, 95% CI: 0.07–0.43 for breast pain). Radiotherapy reduced gynecomastia risk by 52% (RR: 0.48, 95% CI: 0.38–0.59) and breast pain by 34% (RR: 0.66, 95% CI: 0.48–0.90). Anastrozole did not show significant benefit.

Tamoxifen appears to be the most effective strategy for preventing bicalutamide-induced breast events, with radiotherapy serving as a viable alternative, and anastrozole offering no benefit. Further large-scale, high-quality studies are needed to confirm these findings and refine preventive treatment recommendations.